All In Biotech

Investigational drug · Phase 2

Bosmolisib

Also called: BR101801

Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Peripheral T Cell Lymphoma.

Phase 2

Last checked: Nov 19, 2026Latest source record: Jan 28, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 2

Industry-sponsored trials

Phase 2 and 3 trials

1

1 still active

All registered trials

1

Any phase or sponsor naming "Bosmolisib"

First trial start

2026

Feb 2026

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "Bosmolisib", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Peripheral T Cell Lymphoma

Approved drugs for the same conditions: Hematology and blood cancers

Largest trials

Live from ClinicalTrials.gov: studies naming "Bosmolisib" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 6 on PubMed

Also in development for Peripheral T Cell Lymphoma

  • TucidinostatChidamide, HBI-8000Phase 39 trials

    Chipscreen Biosciences, Ltd. · Relapsed/Refractory PTCLT With at Least One Line of Prior Systemic Therapy, Unresectable or Metastatic Melanoma, Progressive Brain Metastasis

  • AZD4205Phase 23 trials

    Dizal Pharmaceuticals · Non-small Cell Lung Cancer, Peripheral T-cell Lymphoma, Peripheral T Cell Lymphoma

  • HH2853Phase 22 trials

    Haihe Biopharma Co., Ltd. · Relapsed/Refractory Peripheral T-Cell Lymphoma (R/R PTCL), FL Lymphoma, Epithelioid Sarcoma

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.